




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 487/16, 471/16, A61K 31/4985, 31/551, A61P 25/00 // (C07D 487/16, 241:00, 239:00, 235:00) (C07D 471/16, 241:00, 235:00, 221:00) (C07D 487/16, 243:00, 239:00, 235:00) (C07D 471/16, 243:00, 235:00, 221:00)	A2	(11) International Publication Number: WO 00/27850 (43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/US99/26984 (22) International Filing Date: 12 November 1999 (12.11.99) (30) Priority Data: 09/190,958 12 November 1998 (12.11.98) US 09/400,744 21 September 1999 (21.09.99) US (71) Applicant (for all designated States except US): NEUROCRINE BIOSCIENCES, INC. [US/US]; 10555 Science Center Drive, San Diego, CA 92121 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): HADDACH, Mustapha [MA/US]; 3545 Arnold Avenue, San Diego, CA 92104 (US). GUO, Zhiqiang [CN/US]; 11036 Caminito Alvarez, San Diego, CA 92126 (US). MCCARTHY, James, R. [US/US]; 4037 Oakleaf Drive, Zionsville, IN 46077 (US). (74) Agents: HERMANN, Karl, R. et al.; SEED and BERRY LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	
(54) Title: CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO  (I) (57) Abstract Compounds are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in warmblooded animals, including stroke. The compounds of this invention have structures (I): (a) wherein n, m, R, R₁, R₂, X and Ar are as defined herein, including stereoisomers and pharmaceutically acceptable salts thereof.		